This 13p penny stock’s on fire! Should I buy it?

This UK penny stock has been making investors a lot of money in recent months. Is it worth buying today as a speculative investment?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Illustration of flames over a black background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Earlier this week, I screened the UK stock market for penny stocks (those with share prices under £1 and markets-caps under £100m) that have strong share price momentum at the moment. It’s fair to say that some interesting companies appeared.

Here, I’m going to look at one of those – Poolbeg Pharma (LSE: POLB). Is this AIM-listed stock, which is currently trading for just 13.45p, worth buying for my portfolio as a high-risk, high-reward investment?

An innovative biopharmaceutical business

Poolbeg Pharma is an under-the-radar biopharmaceutical company that’s developing medicines to address unmet medical needs.

Areas of focus include cancer immunotherapy-induced Cytokine Release Syndrome (CRS), infectious disease, and metabolic conditions like obesity (it’s currently developing an oral weight-loss drug).

On its website, Poolbeg notes that it leverages innovative technologies, such as artificial intelligence (AI), to accelerate drug discovery.

This all sounds interesting to me, especially the AI side of things.

I’m also really interested in the obesity drug angle. Recently, I have bought a few weight-loss drug stocks for my portfolio as I believe this is likely to be a huge investment theme over the next decade.

Huge share price gains

Now recently, this stock has been on fire. Over the last six months, it has risen about 50%.

Most of these gains have been down to news around the company’s POLB 001 drug, which has been shown to reduce cancer immunotherapy-induced CRS in an in vivo model.

Earlier this month, the company announced it had received approval from the US Patent Office for its product. This should strengthen the company’s intellectual property, enhancing the value and attractiveness of POLB 001 to potential pharma partners.

We believe POLB 001 holds immense promise in addressing unmet medical needs in cancer immunotherapy-induced cytokine release syndrome and severe influenza, positively impacting patients and healthcare systems alike. Its impressive data package and strong patent portfolio, coupled with the promising $10bn+ market opportunity in cancer immunotherapy-induced CRS alone, strengthens our confidence in its potential to positively impact global health and generate value for our shareholders.

Poolbeg Pharma CEO Jeremy Skillington

Another factor that’s helped the share price is the appointment of co-founder and substantial shareholder Cathal Friel as Executive Chairman. Friel has an excellent track record in the capital markets, having previously been a co-founder of hVIVO (which is having a lot of success today) and Amryt Pharma, which was acquired for $1.5bn in 2023.

Should I buy?

Looking at recent developments here, my view is this is an exciting company. I think it has lots of potential.

Having said that, it’s really risky from an investment perspective. Today, the company doesn’t have revenues or profits. And there are no guarantees it ever will. That’s the thing about drug development. It’s notoriously unpredictable.

For me personally, the penny stock’s a bit too risky right now. So I won’t be buying it.

But I will be keeping it on my watchlist. When there’s a bit more clarity on the viability of its drugs, and its producing revenues and earnings, I could be interested in investing here.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Small-Cap Shares

Investing Articles

Investors should consider buying this energy AIM stock, up 50% in the past year

AIM stock Afentra has seen a stellar price rise in 12 months to November. I believe there may be room…

Read more »

Small-Cap Shares

This penny stock invests in start-ups. Here’s why I think it could surge

Jon Smith explains how smart investments in young companies could help this penny stock's share price jump in the coming…

Read more »

British Pennies on a Pound Note
Investing Articles

1 ex-penny stock I’d buy for passive income

This writer takes a look at one former penny stock that is trading cheaply and carrying a 4.7% forward-looking dividend…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

2 cheap penny stocks for growth AND dividends!

Royston Wild thinks these penny stocks are great all-rounder options for his portfolio. At current prices, are they too cheap…

Read more »

UK coins (1p & 2p) in a savings glass jar against a plain studio background.
Investing Articles

A penny stock that offers growth, dividends AND value!

Searching for the best penny stock? Here's one to consider that could offer plenty for small-cap investors to sink their…

Read more »

Investing Articles

A company insider just bought 2,916,666 shares of this penny stock!

This penny stock in my ISA has lost over half its value this year. But with directors buying shares recently,…

Read more »

Stacks of coins
Investing Articles

How I’d build an ISA portfolio of penny stocks in 2025

Our writer explains his approach to small-cap investing in his ISA portfolio and highlights a penny share he recently bought…

Read more »

A confident young girl sitting on her own, smiling for a selfie.
Investing Articles

If Mike Ashley becomes boohoo CEO, could the share price rocket higher?

This writer is wondering if the boohoo share price might be ready for a massive recovery, and whether he should…

Read more »